Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Conmed (CNMD) over the last 16 years, with Q4 2025 value amounting to $4.1 million.

  • Conmed's Depreciation & Amortization (CF) fell 316.74% to $4.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $17.1 million, marking a year-over-year increase of 324.0%. This contributed to the annual value of $17.1 million for FY2025, which is 324.0% up from last year.
  • According to the latest figures from Q4 2025, Conmed's Depreciation & Amortization (CF) is $4.1 million, which was down 316.74% from $4.4 million recorded in Q3 2025.
  • Conmed's Depreciation & Amortization (CF)'s 5-year high stood at $4.8 million during Q1 2021, with a 5-year trough of $3.8 million in Q3 2021.
  • In the last 5 years, Conmed's Depreciation & Amortization (CF) had a median value of $4.1 million in 2022 and averaged $4.1 million.
  • Per our database at Business Quant, Conmed's Depreciation & Amortization (CF) tumbled by 1524.07% in 2022 and then skyrocketed by 722.69% in 2025.
  • Quarter analysis of 5 years shows Conmed's Depreciation & Amortization (CF) stood at $4.0 million in 2021, then grew by 1.31% to $4.0 million in 2022, then grew by 0.62% to $4.1 million in 2023, then increased by 3.63% to $4.2 million in 2024, then decreased by 3.17% to $4.1 million in 2025.
  • Its Depreciation & Amortization (CF) was $4.1 million in Q4 2025, compared to $4.4 million in Q3 2025 and $4.5 million in Q2 2025.